EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

GPNMB immunohistochemistry is a useful ancillary tool for the diagnosis of pulmonary lymphangioleiomyomatosis

Fatime Szalai iD, Judit Pápay iD, Katalin Dezső iD, Levente Kuthi iD, Anna Sebestyén iD, András Khoór iD, Ildikó Krencz iD

Histopathology · 2026

DOI: 10.1111/his.70026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Fatime Szalai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Membrane Glycoproteins, Biomarkers, Tumor, Lymphangioleiomyomatosis, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research, Development and Innovation Office, Human Resource Development Operational Program, Hungarian Pulmonology Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Lymphangioleiomyomatosis (LAM) is a PEComa that primarily affects premenopausal women and is associated with the cystic destruction of the lung. Although smooth muscle and melanocytic markers can be helpful, histologic diagnosis of LAM remains challenging, especially in small biopsies. Glycoprotein non‐metastatic melanoma protein B (GPNMB) expression has recently been identified as a highly specific and sensitive immunohistochemical marker for PEComas. Nevertheless, only a few LAM cases have been studied so far. The aim of this study was to assess the utility of GPNMB immunohistochemistry as an ancillary marker in a larger cohort of LAM samples. Methods and results Immunohistochemistry for GPNMB was performed on cases of LAM ( N = 15), potential differential diagnostic mimics ( N = 30) and normal lung tissue ( N = 2). Immunohistochemistry was assessed using the H‐score method; an H‐score above 100 was considered ‘high’. All LAM cases showed strong cytoplasmic expression, with cell membrane accentuation in some areas. In contrast, differential diagnostic mimics were either negative or only weakly positive. Normal lung parenchyma was negative for GPNMB; however, weak‐to‐moderate expression was seen in alveolar macrophages in both the normal and diseased lung tissues in most cases. Considering only ‘high’ positivity, GPNMB immunohistochemistry showed 100% sensitivity and specificity for the diagnosis of LAM in our cohort.

Conclusions

Based on its 100% sensitivity and specificity, GPNMB appears to be a highly valuable immunohistochemical marker for the diagnosis of pulmonary LAM. Besides its diagnostic value, the membrane positivity of GPNMB on LAM cells may predict a response to glembatumumab vedotin, an antibody‐drug conjugate targeting GPNMB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane GlycoproteinsBiomarkers, TumorLymphangioleiomyomatosisLung NeoplasmsHumansFemaleImmunohistochemistryAdultMiddle AgedDiagnosis, DifferentialAgedMaleSensitivity and SpecificityYoung Adult

Stichwörter der Autor:innen

GPNMBimmunohistochemistrylymphangioleiomyomatosis

Substanzen

GPNMB protein, humanMembrane GlycoproteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
  • Department of Surgical and Molecular Pathology, Tumor Pathology Center, National Institute of Oncology, Budapest, Hungary.
  • HUN-REN-ONKOL-TTK-HCEMM Oncogenomics Research Group, National Institute of Oncology, Budapest, Hungary.
  • Department of Laboratory Medicine & Pathology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Fatime Szalai, Judit Pápay, Katalin Dezső, Levente Kuthi, Anna Sebestyén, András Khoór, Ildikó Krencz

Förderung

  • National Research, Development and Innovation Office
  • Human Resource Development Operational Program
  • Hungarian Pulmonology Foundation
  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal

Zitieren

APA

Szalai, F., Pápay, J., Dezső, K., Kuthi, L., Sebestyén, A., Khoór, A., & Krencz, I. (2026). GPNMB immunohistochemistry is a useful ancillary tool for the diagnosis of pulmonary lymphangioleiomyomatosis. Histopathology. https://doi.org/10.1111/his.70026

Vancouver

Szalai F, Pápay J, Dezső K, Kuthi L, Sebestyén A, Khoór A, et al. GPNMB immunohistochemistry is a useful ancillary tool for the diagnosis of pulmonary lymphangioleiomyomatosis. Histopathology. 2026. doi:10.1111/his.70026

BibTeX
@article{Szalai2026,
  author = {Szalai, Fatime and Pápay, Judit and Dezső, Katalin and Kuthi, Levente and Sebestyén, Anna and Khoór, András and Krencz, Ildikó},
  title = {GPNMB immunohistochemistry is a useful ancillary tool for the diagnosis of pulmonary lymphangioleiomyomatosis},
  journal = {Histopathology},
  year = {2026},
  doi = {10.1111/his.70026}
}
Kostenlos starten →